News

NeoPharm has reported a net loss of $1.9 million for the second quarter ended June 30, 2009, as compared to a net loss of $2 million for the

Amgen and GlaxoSmithKline (GSK) would collaborate to share commercialization of Amgen’s monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico, once the product

Cryo-Cell has announced a research and development collaboration agreement with Cryopraxis Cryobiology. Reportedly, the partnership would allow Cryopraxis to conduct clinical studies using Cryo-Cell’s proprietary C’elle menstrual stem

RXi Pharmaceuticals has exercised its option to an exclusive worldwide license to novel technologies from Advirna, to enable in-vivo delivery of RNAi therapeutics. Terms of the agreement were

Eli Lilly and BioMS have reported that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS). The

Sanofi-aventis and Merieux Alliance have signed a strategic agreement for the acquisition of Merieux Alliance’s French subsidiary, ShanH, by Sanofi Pasteur. ShanH owns a majority stake in vaccine

Quark has releases the data suggesting that QPI-1007 prevents progressive retinal ganglion cell (RGC) loss in an increased ocular pressure (IOP) rat model of glaucoma. The experiments done

Taro Pharmaceutical Industries (Taro) has received approval from FDA for its Abbreviated New Drug Application (ANDA) for cetirizine hydrochloride tablets (OTC), 5mg and 10mg (Cetirizine Tablets). The product

Celsion’s global phase III ThermoDox trial for the treatment of primary liver cancer will be extended to Japan by Yakult Honsha’s expertise. The latter is the exclusive licensor